Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G

Rhea-AI Filing Summary

Driehaus Capital Management LLC reported beneficial ownership of 292,144 shares of Cue Biopharma, Inc. common stock on a Schedule 13G. This represents 6.96% of the outstanding common stock. All of these shares are reported with shared voting and shared dispositive power; Driehaus reports no sole voting or dispositive power.

The shares are held in fully discretionary accounts for investment advisory clients, including Driehaus Life Sciences Master Fund, L.P., which has rights with respect to more than 5% of Cue Biopharma’s common stock. Clients retain the economic rights to dividends and sale proceeds.

Key Figures

Shares beneficially owned: 292,144 shares Percent of class: 6.96% Sole voting power: 0 +2 more

5 metrics

Shares beneficially owned 292,144 shares Common Stock of Cue Biopharma reported by Driehaus Capital Management LLC

Percent of class 6.96% Portion of Cue Biopharma common stock represented by Driehaus’s reported holdings

Sole voting power 0 Shares of Cue Biopharma over which Driehaus has sole voting power

Shared voting power 292,144 shares Shares of Cue Biopharma over which Driehaus has shared voting power

Shared dispositive power 292,144 shares Shares of Cue Biopharma over which Driehaus has shared power to dispose

Key Terms

beneficially owned, shared voting power, dispositive power, percent of class, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 292144"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 292,144.00 7 | Sole Dispositive Power 0.00 8 | Shared"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"| Sole Dispositive Power 0.00 8 | Shared Dispositive Power 292,144.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

percent of class financial

"Item 4. | Ownership (b) | Percent of class: 6.96 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

investment advisory client financial

"is an investment advisory client of DCM. The shares reported by"

FAQ

What stake in Cue Biopharma (CUE) does Driehaus Capital Management report?

Driehaus Capital Management reports beneficial ownership of 292,144 shares of Cue Biopharma common stock, representing 6.96% of the class. The position is reported on a Schedule 13G as an investment advisory holding for client accounts.

Does Driehaus Capital have sole or shared voting power over CUE shares?

Driehaus Capital reports 0 shares with sole voting power and 292,144 shares with shared voting power in Cue Biopharma. The same 292,144 shares are also reported with shared dispositive power, reflecting its role as investment adviser.

Who ultimately benefits from the Cue Biopharma (CUE) shares held by Driehaus Capital?

The economic benefits, including dividends and sale proceeds, accrue to Driehaus Capital’s advisory clients. These include Driehaus Life Sciences Master Fund, L.P., which has rights with respect to more than 5% of Cue Biopharma’s common stock.

What class of Cue Biopharma (CUE) securities is covered in this Schedule 13G?

The Schedule 13G filing covers Common Stock of Cue Biopharma, Inc., identified by CUSIP number 22978P205. Driehaus Capital Management’s reported holdings and percentage relate specifically to this class of securities.

Why is Driehaus Life Sciences Master Fund mentioned in the Cue Biopharma (CUE) 13G?

Driehaus Life Sciences Master Fund, L.P. is an investment advisory client of Driehaus Capital. It has rights with respect to more than 5% of Cue Biopharma’s common stock, so its interest is highlighted in the ownership description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 07:38 AM Accepted by SEC EDGAR 08/14/2026 - 07:37 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cue Biopharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

22978P205

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 22978P205

1

Names of Reporting Persons

DRIEHAUS CAPITAL MANAGEMENT LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 292,144.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 292,144.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

292,144.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.96 %

12

Type of Reporting Person (See Instructions)

IV

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cue Biopharma, Inc.
(b)	Address of issuer's principal executive offices: 40 Guest Street, Boston, MA 02135
Item 2.
(a)	Name of person filing: Driehaus Capital Management LLC
(b)	Address or principal business office or, if none, residence: 25 East Erie Street, Chicago, Illinois 60611
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 22978P205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 292144
(b)	Percent of class: 6.96 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 292144
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 292144
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Driehaus Life Sciences Master Fund, L.P. (DLSM), a Cayman Islands exempted company, is an investment advisory client of DCM. The shares reported by Driehaus Capital Management LLC (DCM) are held by two clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. The clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sales of, the securities covered by this Statement. DLSM has the right and power with respect to more than 5% of the shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DRIEHAUS CAPITAL MANAGEMENT LLC

Signature:	Janet McWilliams
Name/Title:	General Counsel
Date:	08/14/2026